本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Bioxcel Therapeutics Inc.

3.68
-0.5550-13.12%
成交量:178.99萬
成交額:679.66萬
市值:5,349.59萬
市盈率:-0.30
高:3.94
開:3.93
低:3.64
收:4.23
52周最高:13.36
52周最低:1.17
股本:1,455.67萬
流通股本:551.26萬
量比:0.80
換手率:32.47%
股息:- -
股息率:- -
每股收益(TTM):-12.2842
每股收益(LYR):-23.5105
淨資產收益率:-1766.94%
總資產收益率:-68.72%
市淨率:-0.50
市盈率(LYR):-0.16

資料載入中...

2024/06/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/06/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/06/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/06/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/06/12

重要事件披露

Form 8-K - Current report
2024/06/06

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/06/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/05/09

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/09

重要事件披露

Form 8-K - Current report
2024/04/22

重要事件披露

Form 8-K - Current report
2024/04/10

重要事件披露

Form 8-K - Current report
2024/04/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/03

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/25

重要事件披露

Form 8-K - Current report
2024/03/22

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]